Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
The ultimate guide to navigating CMC in drug development
CMC is crucial in drug development, ensuring quality and scalability. Experts discussed overcoming CMC challenges, emphasizing early-stage de-risking, collaboration, selecting the right CMO, and leveraging AI. Effective CMC implementation is vital for drug development success.
Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over
Non-cystic fibrosis bronchiectasis market driven by rising prevalence, early diagnosis, and drug development. Over 15 companies, including Zambon SpA, Insmed, and AstraZeneca, are developing 15+ pipeline therapies. Key drugs in trials include Colistimethate sodium, Benralizumab, and Brensocatib.
How logistics shape the success of rare disease trials
Experts at Clinical Trials in Rare Diseases Europe 2024 and Clinical Data Management Innovation Europe 2024 will discuss innovative trial designs, real-world evidence, and AI integration in clinical data management, focusing on rare disease treatments and patient inclusivity.
Sleep apnea: biotechs snore points in the therapeutic space
Research on sleep apnea includes CPAP machines, mouth guards, and throat exercises. Lilly's tirzepatide showed significant AHI reduction in phase 3 trials. Epilepsy drug sulthiame also showed promise in sleep apnea trials. Apnimed's AD109 targets hypoglossal motor neurons, improving airway signals. Gut microbiome changes linked to sleep apnea severity suggest patient-specific therapies.
FDA Clears Novavax to Resume Trials of Covid-19 and Flu Combo Vaccine
Novavax received FDA approval to resume clinical trials for its Covid-19 and influenza combination vaccine (CIC) and standalone influenza vaccines after a month-long hold. The Phase III trial will evaluate the CIC vaccine's efficacy in adults aged 65 and older, comparing its immune response to standard flu and Covid-19 vaccines. Novavax aims to commence enrolment by the end of 2024, with preliminary results expected by mid-2025.
Related Clinical Trials:
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift
FDA expands DUPIXENT use for COPD, offering new treatment options for patients. COPD affects 44 million in 7MM, with cases expected to rise. DUPIXENT targets IL-4 and IL-13 pathways, reducing exacerbations and improving lung function.
A Revolution in Antibody Therapy: Q & A with Randy Noelle, PhD
Investigators have been developing CD40L antagonists to treat autoimmune diseases like MS, IBD, and lupus. CD40L, discovered by Randy Noelle, is central to the immune system and blocking it can prevent autoimmunity. Despite initial setbacks, Noelle's engineered antibody, frexalimab, has shown safety and efficacy in clinical trials for MS, lupus, and type 1 diabetes.
Pharma 4.0 Market Size, Share | Growth CAGR Of 18.9%
The Global Pharma 4.0 Market is projected to grow from US$ 11.9 Billion in 2023 to US$ 67.7 Billion by 2033, driven by digital transformation strategies, AI, IoT, and blockchain. Key segments include AI & ML leading technology with 33.4% share, drug discovery & development with 37.8%, and pharmaceutical companies as the dominant end-user with 42.6%. North America leads with 39.7% market share, while Asia Pacific is expected to grow fastest.
Sanofi, OpenAI, Formation launch Muse, an AI tool for patient recruitment
Sanofi, OpenAI, and Formation Bio's Muse, an AI-powered tool built on GPT-4, aims to expedite patient recruitment in clinical trials, addressing costly delays. Muse segments patients and suggests engagement strategies, with human oversight ensuring accuracy and compliance.
Inside the AI-Healthcare Boom: Breakthroughs in Diagnostics and Personalized Treatment
AI in healthcare is booming, with Mayo Clinic and Elon Musk's Grok AI leading the charge. Major tech companies like Nvidia, Google, and Microsoft showcased healthcare AI tools at the HLTH conference. Avant Technologies and Ainnova Tech formed a joint venture to advance early disease detection using AI, targeting a $67.4 billion market by 2027. Other companies like Recursion Pharmaceuticals, Exscientia, Absci Corporation, and Twist Bioscience are also making strides in AI-driven healthcare innovations.
© Copyright 2024. All Rights Reserved by MedPath